The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

被引：94

作者：

Kaiser-Guignard, Julie ^{[1
]}

Canellini, Giorgia ^{[2
]}

Lion, Niels ^{[2
]}

Abonnenc, Melanie ^{[2
]}

Osselaer, Jean-Claude ^{[2
]}

Tissot, Jean-Daniel ^{[2
]}

机构：

[1] CHU Vaudois, Serv Hematol, CH-1011 Lausanne, Switzerland

[2] Serv Reg Vaudois Transfus, CH-1066 Epalinges, Switzerland

来源：

BLOOD REVIEWS | 2014年 / 28卷 / 06期

关键词：

Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelets; Platelet concentrates; Riboflavin; Transfusion; IN-VITRO EVALUATION; INTERSTRAND CROSS-LINKS; INTERCEPT BLOOD SYSTEM; THERAPEUTIC-EFFICACY; FUNCTIONAL-CHARACTERISTICS; PHOTOCHEMICAL TREATMENT; AMOTOSALEN-HCL; BLEEDING COMPLICATIONS; PROTEIN-SYNTHESIS; ADDITIVE SOLUTION;

D O I：

10.1016/j.blre.2014.07.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity. (C) 2014 The Authors. Published by Elsevier Ltd.

引用

页码：235 / 241

页数：7

共 50 条

[31] Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light
Cardo, Lisa J.
Salata, Jeanne
Mendez, Juan
Reddy, Heather
Goodrich, Raymond
TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (02) : 131 - 137
[32] Metabolomics study of platelet concentrates photochemically treated with amotosalen and UVA light for pathogen inactivation
Johannsson, Freyr
Arnason, Niels A.
Landroe, Ragna
Gudmundsson, Sveinn
Sigurjonsson, Olafur E.
Rolfsson, Ottar
TRANSFUSION, 2020, 60 (02) : 367 - 377
[33] Robust Inactivation of Mayaro Virus in Platelet Concentrates and Red Blood Cells Using Nucleic Acid Targeting Pathogen Reduction Technologies (PRT)
Maria, Felicia Santa
Laughhunn, Andrew
Girard, Yvette
Bringmann, Peter
Lanteri, Marion
Stassinopoulos, Adonis
TRANSFUSION, 2017, 57 : 47A - 48A
[34] Comparison of Clinical Efficacy and Safety of the Pathogen Reduced and γ-Irradiated Platelet Concentrates
Azimova, Muhayyokhon
Galstyan, Gennadiy
Gaponova, Tatjana
Drokov, Mihail
Dubinkin, Igor
Zhuravlev, Vladimir
Mihaylova, Elena
TRANSFUSION, 2017, 57 : 169A - 169A
[35] Impact of Platelet Pathogen Inactivation on Blood Component Utilization Inventory
Fachini, Roberta
Scuracchio, Patricia
Achkar, Ruth
Fontao-Wendel, Rita
Wendel, Silvano
TRANSFUSION, 2021, 61 : 48A - 49A
[36] The Impact of Amotosalen Photochemical Pathogen Inactivation on Human Platelet Lysate
Delabie, Willem
De Bleser, Dominique
Vandewalle, Vicky
De Prest, Marie-Laurence
Vandekerckhove, Philippe
Compernolle, Veerle
Feys, Hendrik B.
CURRENT STEM CELL RESEARCH & THERAPY, 2024,
[37] Pathogen-Reduction for Platelet Concentrates
Weber, C. F.
Heim, M. U.
CLINICAL LABORATORY, 2011, 57 (5-6) : 293 - 295
[38] Clinical Experience with Pathogen Inactivation of Platelet Components for Transfusion Support
Cazenave, Jean-Pierre
Waller, Chantal
Mendel, Isabelle
Kientz, Daniel
Kande, Gerard
Raidot, Jean-Pierre
Wiesel, Marie-Louise
Laforet, Michel
Isola, Herve
PROGRESS AND CHALLENGES IN TRANSFUSION MEDICINE, HEMOSTASIS AND HEMOTHERAPY: STATE OF THE ART 2008, 2008, : 248 - 263
[39] Pathogen reduction or inactivation technologies for platelet components: Does decision making have to await further clinical trials?
Garraud, Olivier
TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (06) : 797 - 798
[40] Plasma/platelet pathogen inactivation
Hervig, T. A.
Apelseth, T.
Sondergaard, M.
ISBT SCIENCE SERIES, VOL 1, NO 1: STATE OF THE ART PRESENTATIONS, 2006, 1 (01): : 227 - 229

← 1 2 3 4 5 →